Atrial fibrillation is associated with higher stroke risk but not with higher mortality in patients with heart failure: A nationwide analysis
In brief
In heart failure, atrial fibrillation raises stroke risk but not death risk
In a Swedish study of nearly 705,000 people with heart failure, atrial fibrillation was linked to higher stroke risk but not to a higher risk of death on its own. Stroke risk declined over time as anticoagulant use rose, with a larger improvement among women; the study cannot show that wider treatment caused the decline.
- Journal
- Med (New York, N.Y.) (Q1)
- Published
- 19 November 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Johan Sundström, Stefan Gustafsson, Daniel Lindholm
- PMID
- 43057239
- DOI
- 10.1016/j.medj.2026.101363
Why clinicians should know about it
- Picked for Epidemiology (paper of the day, 21 November 2026): Nationwide cohort models stroke, mortality, and treatment trends
Abstract
BACKGROUND: While atrial fibrillation/flutter (AF) has been associated with increased risk of mortality in patients with heart failure (HF), it is unknown whether AF confers an increased risk on its own, i.e., not mediated through the increased risk of stroke. We aimed to investigate the age- and sex-specific prognostic impact of AF and stroke (alone and in combination) in patients with HF by using multistate modeling to account for events occurring during follow-up. Secondary aims were to investigate temporal trends in transition rates and in anticoagulant use in patients with AF and HF. METHODS: This was a Swedish nationwide cohort study that included adult patients with HF diagnosed between 2004 and 2025. We used multistate modeling to account for occurrences of AF and stroke both at baseline and during follow-up. With Poisson regression in generalized additive models, we assessed age- and sex-specific transition rates between the different disease states, and in a separate model including time period, we assessed temporal trends in transition rates. Finally, as oral anticoagulants influence stroke risk in patients with atrial fibrillation, we estimated temporal, sex-specific trends in their use. FINDINGS: We identified 704,852 patients (47% women) with HF, who were followed for a total of 2.9 million person-years. AF was associated with an increased risk of stroke but did not associate with an increased risk of death on its own. In the early study period, women, compared with men, were less likely to receive oral anticoagulants, but their use increased over time, more in women than in men. During the same period, there was a decline in stroke risk, with a greater absolute improvement in women than in men. CONCLUSIONS: In this study of patients with HF, AF was not associated with an elevated direct risk of mortality. Over time, the risk of stroke decreased in patients with HF and AF, temporally coinciding with a marked uptake of direct-acting oral anticoagulant (DOAC) use, with the largest improvement seen among women. FUNDING: This study was supported by unrestricted funding from Anders Wiklöf.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.